SCHEMBL1997253

SCHEMBL1997253

O=Cc1cc(-c2ccccc2)ccc1CN1CC(=O)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.38
EPHX2 P34913 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
TDP2 O95551 1/20 0.36
PTPN1 P18031 5/20 0.36
PTPN2 P17706 2/20 0.36
ENPP2 Q13822 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
TNKS2 Q9H2K2 1/20 0.33
PTP4A3 O75365 1/20 0.33
BACE1 P56817 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SRC P12931 1/20 0.32
ERN1 O75460 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001787 0.76 ENPP2 (0.57) EPHX2DDB1CRBNENPP2MEN1
SCHEMBL1996203 0.74 TRIM24 (0.43) EPHX2DDB1CRBNENPP2
SCHEMBL18634178 0.74 BACE1 (0.47) CRBNALDH1A1BACE1
SCHEMBL3694689 0.71 CHKA (0.51) MEN1ALDH1A1KMT2ABACE1NPC1
SCHEMBL8175589 0.70 KDM4E (0.48) PTPN1PTPN2KDM4EMEN1ALDH1A1
SCHEMBL9850086 0.69 DDB1 (0.69) EPHX2DDB1CRBNENPP2MEN1
SCHEMBL1011633 0.69 DDB1 (0.69) EPHX2DDB1CRBNENPP2MEN1
SCHEMBL9850110 0.68 DDB1 (0.67) EPHX2DDB1CRBNENPP2MEN1
SCHEMBL8633466 0.67 CYP1A2 (0.50) EPHX2DDB1CRBNKDM4EMEN1
SCHEMBL6983619 0.67 MAPT (0.46) PTPN1PTPN2KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 MAT2A 3847/4885EPHX2 3501/4885DDB1 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.